Mon - Fri 09:00-18:00 0207 060 3773
Email info@boundarycapital.com

Blog

Boundary Capital Newsletter: Autumn 2018

  View From The Pavilion Your newsletter from Boundary Capital. We’re delighted to bring you the latest news and updates from the Boundary Capital portfolio of high-tech movers and shakers. GROWTH INVEST: Adviser Hour – Series 1 Dan Somers, Managing Partner at Boundary Capital talks to Lawrence Gosling, Editor-in-Chief at GrowthBusiness.com on the GrowthInvest Adviser […]

Boundary Capital to present at Kuber Ventures seminar

Boundary Capital is delighted to be presenting at the Kuber Ventures seminar at The Royal Automobile Club 5 July. EIS is set to play a critical role in the growth of the UK economy and both understanding and managing risk is central to this exciting dynamic growth oriented environment. Join us and Kuber Ventures at […]

Boundary Capital in the Press: Finance Digital, Why Some Investors Are Going The Extra Mile

Our Managing Partner Dan Somers talks to Finance Digital talking about why some investors are going the extra mile. Investing in early stage technology businesses is a risky business. If you get it right investing in a disruptive business like WhatsApp or Alibaba can generate huge exits: a whopping $22Bn and $25Bn respectively (Sequoia Capital turned […]

Boundary in the Press: What Investment, AB-Polyblok files for patent of potentially revolutionary dementia drug

What Investment has published the latest news from Boundary Capital’s portfolio company AB Polyblok. Boundary Capital investment company AB-Polyblok has today filed a patent application following the results of in-vitro & in-vivo experiments that have shown that their drug appears to reverse the effects of the key misfolded proteins associated with all three dementia diseases […]

Boundary Board member backs first dedicated life sciences crowdfunding platform

Adrian Parton, MBE, of Boundary Capital has backed Capital Cell, Europe’s first dedicated Life Sciences crowdfunding platform. Capital Cell works with companies whose technology is based on biology or healthcare to secure the investment they need to progress their innovative, potentially life-changing ideas. Capital Cell’s model is to support early stage companies, with seed stage […]